These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24814141)

  • 1. Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression.
    Fukui N; Suzuki Y; Sugai T; Watanabe J; Ono S; Tsuneyama N; Someya T
    Psychiatry Res; 2014 Aug; 218(3):353-5. PubMed ID: 24814141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.
    Kocabas NA; Faghel C; Barreto M; Kasper S; Linotte S; Mendlewicz J; Noro M; Oswald P; Souery D; Zohar J; Massat I
    Int Clin Psychopharmacol; 2010 Jul; 25(4):218-27. PubMed ID: 20531207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).
    Kocabas NA
    CNS Neurol Disord Drug Targets; 2012 May; 11(3):264-72. PubMed ID: 22483292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.
    Benedetti F; Dallaspezia S; Colombo C; Lorenzi C; Pirovano A; Smeraldi E
    Eur Psychiatry; 2010 Dec; 25(8):476-8. PubMed ID: 20619611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response.
    Ji Y; Biernacka J; Snyder K; Drews M; Pelleymounter LL; Colby C; Wang L; Mrazek DA; Weinshilboum RM
    Pharmacogenomics J; 2012 Feb; 12(1):78-85. PubMed ID: 20877297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings.
    Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.
    Houston JP; Kohler J; Ostbye KM; Heinloth A; Perlis RH
    Psychiatry Res; 2011 Oct; 189(3):475-7. PubMed ID: 21788083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy.
    Anttila S; Huuhka K; Huuhka M; Illi A; Rontu R; Leinonen E; Lehtimäki T
    Pharmacogenomics J; 2008 Apr; 8(2):113-6. PubMed ID: 17700596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.
    Hopkins SC; Reasner DS; Koblan KS
    Psychiatry Res; 2013 Aug; 208(3):285-7. PubMed ID: 23706899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suitable dose and duration of fluvoxamine administration to treat depression.
    Morishita S; Arita S
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study.
    Schosser A; Calati R; Serretti A; Massat I; Kocabas NA; Papageorgiou K; Linotte S; Mendlewicz J; Souery D; Zohar J; Juven-Wetzler A; Montgomery S; Kasper S
    Eur Neuropsychopharmacol; 2012 Apr; 22(4):259-66. PubMed ID: 21940152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression.
    Szegedi A; Rujescu D; Tadic A; Müller MJ; Kohnen R; Stassen HH; Dahmen N
    Pharmacogenomics J; 2005; 5(1):49-53. PubMed ID: 15520843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder.
    Leuchter AF; McCracken JT; Hunter AM; Cook IA; Alpert JE
    J Clin Psychopharmacol; 2009 Aug; 29(4):372-7. PubMed ID: 19593178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association analysis of COMT/MTHFR polymorphisms and major depressive disorder in Chinese Han population.
    Shen X; Wu Y; Guan T; Wang X; Qian M; Lin M; Shen Z; Sun J; Zhong H; Yang J; Li L; Yuan Y
    J Affect Disord; 2014 Jun; 161():73-8. PubMed ID: 24751310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of catechol-O-methyltransferase polymorphisms on pain is modified by depressive symptoms.
    Schwahn C; Grabe HJ; Meyer zu Schwabedissen H; Teumer A; Schmidt CO; Brinkman C; Kocher T; Nauck M; Völzke H; Biffar R; Bernhardt O
    Eur J Pain; 2012 Jul; 16(6):878-89. PubMed ID: 22337325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functional Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with depression and motivation in men from a Swedish population-based study.
    Åberg E; Fandiño-Losada A; Sjöholm LK; Forsell Y; Lavebratt C
    J Affect Disord; 2011 Mar; 129(1-3):158-66. PubMed ID: 20828831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression.
    Chiesa A; Lia L; Alberti S; Lee SJ; Han C; Patkar AA; Pae CU; Serretti A
    Int J Psychiatry Clin Pract; 2014 Jun; 18(2):97-102. PubMed ID: 24555772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression.
    Tunbridge E; Burnet PW; Sodhi MS; Harrison PJ
    Synapse; 2004 Feb; 51(2):112-8. PubMed ID: 14618678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association analysis of the catechol-O-methyltransferase /methylenetetrahydrofolate reductase genes and cognition in late-onset depression.
    Wang X; Wang Z; Wu Y; Yuan Y; Hou Z; Hou G
    Psychiatry Clin Neurosci; 2014 May; 68(5):344-52. PubMed ID: 24373005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.